FDA grants breakthrough therapy status for Nuvalent’s NVL-655
The US FDA has granted breakthrough therapy designation (BTD) for Nuvalent’s NVL-655 for the treatment of non-small cell lung cancer.
The US FDA has granted breakthrough therapy designation (BTD) for Nuvalent’s NVL-655 for the treatment of non-small cell lung cancer.
What's Your Reaction?
